«These results
enable us to determine whether potential treatments will be
effective against patients» symptoms by testing them first in healthy volunteers and defining the best
doses based on objective physiological data before conducting costly clinical trials,» said Jeffrey Lieberman, MD, the Lawrence C. Kolb Professor and Chairman of the Department of Psychiatry at CUMC, and Principal Investigator of this study.